blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4072569

EP4072569 - METHOD OF PREPARATION OF THE TRANSFER FACTOR MEDICINE, TRANSFER FACTOR MEDICINE, METHOD OF TESTING ITS BIOLOGICAL ACTIVITY, PHARMACEUTICAL FORM AND ITS USE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  19.01.2024
Database last updated on 20.12.2024
FormerRequest for examination was made
Status updated on  16.09.2022
FormerThe international publication has been made
Status updated on  17.12.2021
Formerunknown
Status updated on  05.05.2021
Most recent event   Tooltip24.05.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Aumed, a.s.
Komoranska 326/63
14300 Praha 4 / CZ
[2022/42]
Inventor(s)01 / VRONKA, Juraj
16300 Praha 17 / CZ
 [2022/42]
Representative(s)Danek, Vilém
Danek & Partners
Vinohradská 17
120 00 Praha 2 / CZ
[2022/42]
Application number, filing date21721385.925.03.2021
[2022/42]
WO2021CZ00014
Priority number, dateCZ2020000034212.06.2020         Original published format: CZ 20200342
[2022/42]
Filing languageCS
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021249581
Date:16.12.2021
Language:EN
[2021/50]
Type: A1 Application with search report 
No.:EP4072569
Date:19.10.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 16.12.2021 takes the place of the publication of the European patent application.
[2022/42]
Search report(s)International search report - published on:EP16.12.2021
ClassificationIPC:A61K35/14, A61K38/17, B01D61/00
[2022/42]
CPC:
A61K35/14 (EP); A61K35/15 (CZ); A61K38/17 (EP);
A61K38/1709 (CZ); A61K9/0056 (CZ); A61K9/19 (CZ);
A61K9/20 (CZ); A61P37/00 (CZ); B01D61/027 (EP);
B01D61/146 (CZ); B01D61/58 (EP); B01D71/56 (EP);
G01N33/15 (CZ); G01N33/5008 (CZ); B01D2311/10 (EP);
B01D61/145 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/42]
TitleGerman:VERFAHREN ZUR HERSTELLUNG DES ARZNEIMITTELS MIT TRANSFERFAKTOR, ARZNEIMITTEL MIT TRANSFERFAKTOR, VERFAHREN ZUM TESTEN SEINER BIOLOGISCHEN AKTIVITÄT, PHARMAZEUTISCHE FORM UND SEINE VERWENDUNG[2022/42]
English:METHOD OF PREPARATION OF THE TRANSFER FACTOR MEDICINE, TRANSFER FACTOR MEDICINE, METHOD OF TESTING ITS BIOLOGICAL ACTIVITY, PHARMACEUTICAL FORM AND ITS USE[2022/42]
French:PROCÉDÉ DE PRÉPARATION DE MÉDICAMENT À FACTEUR DE TRANSFERT, MÉDICAMENT À FACTEUR DE TRANSFERT, PROCÉDÉ DE TEST DE SON ACTIVITÉ BIOLOGIQUE, FORME PHARMACEUTIQUE ET SON UTILISATION[2022/42]
Entry into regional phase12.07.2022National basic fee paid 
21.06.2022Designation fee(s) paid 
21.06.2022Examination fee paid 
Examination procedure21.06.2022Examination requested  [2022/42]
21.06.2022Date on which the examining division has become responsible
17.01.2023Amendment by applicant (claims and/or description)
23.01.2024Despatch of a communication from the examining division (Time limit: M04)
23.05.2024Reply to a communication from the examining division
Fees paidRenewal fee
26.05.2023Renewal fee patent year 03
27.03.2024Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.03.202303   M06   Fee paid on   26.05.2023
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]WO2007143957  (SEVAPHARMA A S [CZ], et al) [X] 17-23 * the whole document * [Y] 1-23;
 [XY]  - DEMECKOVÁ VLASTA ET AL, "Immodin and its immune system supportive role in paclitaxel therapy of 4T1 mouse breast cancer", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, (20170224), vol. 89, doi:10.1016/J.BIOPHA.2017.02.034, ISSN 0753-3322, pages 245 - 256, XP029987180 [X] 17-23 * page 246 * [Y] 1-23

DOI:   http://dx.doi.org/10.1016/j.biopha.2017.02.034
 [XY]  - CARDOSO F M ET AL, "New and cost effective cell-based assay for Dialyzed Leukocyte Extract (DLE)-induced Jurkat cells proliferation under azathioprine treatment", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, ELSEVIER B.V, AMSTERDAM, NL, (20170131), vol. 138, doi:10.1016/J.JPBA.2017.01.052, ISSN 0731-7085, pages 100 - 108, XP029949113 [X] 12-17 * the whole document * [Y] 1-23

DOI:   http://dx.doi.org/10.1016/j.jpba.2017.01.052
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.